Pirtobrutinib (LOXO-305)

  Cat. No.:  DC50020   Featured
Pirtobrutinib (LOXO-305)
Chemical Structure
2101700-15-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
LOXO-305 is an investigational, novel, selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. LOXO-305 was designed to reversibly bind BTK, preserve activity in the presence of the acquired resistance, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors.LOXO-305 is a highly selective, non-covalent BTKi that inhibits both wild type (WT) and C481-mutated BTK with equal low nM potency was developed.
Cas No.: 2101700-15-4
Chemical Name: 1H-Pyrazole-4-carboxamide, 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1S)-2,2,2-trifluoro-1-methylethyl]
Synonyms: LOXO-305; RXC-005;LOXO 305;LOXO305;RXC 005;RXC005
SMILES: FC([C@]([H])(C([H])([H])[H])N1C(=C(C(N([H])[H])=O)C(C2C([H])=C([H])C(C([H])([H])N([H])C(C3C([H])=C(C([H])=C([H])C=3OC([H])([H])[H])F)=O)=C([H])C=2[H])=N1)N([H])[H])(F)F
Formula: C22H21F4N5O3
M.Wt: 479.42
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description:
Target:
In Vivo:
In Vitro:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_26099_DC50020_2101700-15-4
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC60200 SEP-363856 SEP-363856 isomer
DC60199 Bifluranol Bifluranol (brand name Prostarex; former developmental code name BX-341) is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol that has been used as an antiandrogen in the United Kingdom in the treatment of benign prostatic hyperplasia. It exerts functional antiandrogen effects by binding to and activating the estrogen receptor in the pituitary gland, consequently suppressing the secretion of luteinizing hormone (and hence acting as an antigonadotropin) and thereby reducing gonadal androgen production and systemic androgen levels.
DC60198 GN44028 GN44028 inhibits HIF-1α. GN44028 surpresses HIF-1α transcriptional activity without affecting both HIF-1α protein accumulation and HIF-1α/HIF-1β heterodimerization in nuclei under the hypoxic conditions, suggesting that GN44028 probably affectes the transcriptional pathway induced by the HIF-1α/HIF-1β heterodimer.
DC60197 Pinacol
DC60196 K-Ras G12C-IN-4
DC60195 Batefenterol Succinate Batefenterol Succinate is a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.
DC60194 ARQ-087·2HCl
DC60193 Sitagliptin phosphate
DC60191 Tenofovir Alafenamide Impurity 1
DC60190 TAS4464 TAS4464 is a highly potent and selective inhibitor of NEDD8 (IC50 of 0.955 nM). TAS4464 selectively inhibited NAE relative to the other E1s UAE and SAE. TAS4464 treatment inhibited cullin neddylation and subsequently induced the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IκBα in human cancer cell lines. TAS4464 showed greater inhibitory effects than those of the known NAE inhibitor MLN4924 both in enzyme assay and in cells.